✦ LIBER ✦

Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement

✍ Scribed by Baig, Nisar A.; Taylor, Ronald P.; Lindorfer, Margaret A.; Church, Amy K.; Laplant, Betsy R.; Pavey, Emily S.; Nowakowski, Grzegorz S.; Zent, Clive S.

Book ID: 126646000
Publisher: Informa plc
Year: 2012
Tongue: English
Weight: 436 KB
Volume: 53
Category: Article
ISSN: 1042-8194
DOI: 10.3109/10428194.2012.681657

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Induced Resistance to Ofatumumab-Mediate

Induced Resistance to Ofatumumab-Mediated Cell Clearance Mechanisms, Including Complement-Dependent Cytotoxicity, in Chronic Lymphocytic Leukemia

✍ Baig, N. A.; Taylor, R. P.; Lindorfer, M. A.; Church, A. K.; LaPlant, B. R.; Pet 📂 Article 📅 2014 🏛 American Association of Immunologists 🌐 English ⚖ 760 KB

5.15 Resistance to Complement-Dependent

5.15 Resistance to Complement-Dependent Cytotoxicity in Chronic Lymphocytic Leukemia Cells from Patients Treated with Ofatumumab

✍ Nisar A. Baig; Ronald P. Taylor; Margaret A. Lindorfer; Amy K. Church; Betsy R. 📂 Article 📅 2011 🏛 Elsevier 🌐 English ⚖ 217 KB

Complement-dependent and complement-inde

Complement-dependent and complement-independent cytotoxicity of polyclonal antithymocyte globulins in chronic lymphocytic leukemia

✍ Francis A. Ayuk; Nabil Atassi; Gunther Schuch; Sormeh Mina; Lubin Fang; Carsten 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 475 KB

Quantitative analyses reveal substantial

Quantitative analyses reveal substantial differences between Ofatumumab (OFA) and Rituximab (RTX) in mediating Complement-Dependent Cytotoxicity (CDC) of B cell lines and Chronic Lymphocytic Leukemia (CLL) cells

✍ P. Taylor 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 81 KB

Direct and complement dependent cytotoxi

Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early–intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab

✍ Clive S. Zent; Charla R. Secreto; Betsy R. LaPlant; Nancy D. Bone; Timothy G. Ca 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 373 KB

The mechanism of cytotoxicity of alemtuzumab and rituximab in chronic lymphocytic leukemia (CLL) is not well understood. We obtained fresh CLL cells from early-intermediate stage high-risk patients just prior to treatment with alemtuzumab and rituximab to study mechanisms of action and resistance. A

Complement-Dependent Cellular Cytotoxici

Complement-Dependent Cellular Cytotoxicity: Lymphoblastoid Lines That Activate Complement Component 3 (C3) and Express C3 Receptors Have Increased Sensitivity to Lymphocyte-Mediated Lysis in the Presence of Fresh Human Serum

✍ Oscar F. Ramos, Gabriella Sármay, Eva Klein, Eitan Yefenof and János Gergely 📂 Article 📅 1985 🏛 National Academy of Sciences 🌐 English ⚖ 1019 KB